You are here

  • Home
  • Archive
  • Volume 11, Issue 1
  • Impact of early caffeine administration on respiratory outcomes in very preterm infants initially receiving invasive mechanical ventilation

Article Text

Article menu

Download PDFPDF

Paediatric lung disease
Impact of early caffeine administration on respiratory outcomes in very preterm infants initially receiving invasive mechanical ventilation
  1. Yarui Zhao1,
  2. Lidan Zhang2,
  3. Mingtao Zhang3,
  4. Shuai Li4,
  5. Xuemei Sun5,
  6. Xiaolin Sun6,
  7. Guo Yao7,
  8. Cong Li8,
  9. Minmin Li9,
  10. Chunyu Song10,
  11. Haiying He11,
  12. Yongfeng Jia12,
  13. Bing Jv13,
  14. Yonghui Yu9,
  15. Yun Zhu1 and
  16. Li Wang2
  1. 1Party Committee Office, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
  2. 2The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China
  3. 3Department of Neonatology, Hebei PetroChina Central Hospital, Langfang, China
  4. 4Department of Neonatology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China
  5. 5Department of Neonatology, Linyi People's Government, Linyi, Shandong, China
  6. 6Department of Neonatology, Women and Children’s Healthcare Hospital of Linyi, Linyi, China
  7. 7Department of Neonatology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China
  8. 8Department of Neonatology, Liaocheng People's Hospital, Liaocheng City, China
  9. 9Department of Neonatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
  10. 10Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
  11. 11Department of Neonatology, The Third Hospital of Bao Gang Group, Baotou, China
  12. 12Department of Neonatology, Shangluo Central Hospital, Shangluo, China
  13. 13Blood Center of Shangdong Province, Jinan, China
  1. Correspondence to Dr Yonghui Yu; alice20402{at}126.com

Abstract

Objective The guidelines recommend early caffeine administration for preterm infants requiring non-invasive mechanical ventilation since earlier treatment is associated with better outcomes. The objective was to evaluate the impact of early caffeine therapy (within 24 hours after birth) on respiratory outcomes in very preterm infants who were initially receiving invasive mechanical ventilation.

Methods This was an observation cohort study from 1 January 2018 to 31 December 2022 based on a database that was prospectively collected and maintained. Infants who initially received invasive mechanical ventilation were divided into two groups based on the timing of caffeine initiation: within the first 24 hours after birth (early) and within 48 hours of birth or later (late). Generalised linear mixed models with a random effect model for the centre were used to assess the impact of different caffeine initiation times on neonatal outcomes.

Results Among the cohort of 9880 infants born at <32 weeks gestation, 2381 were eligible for this study (early initiation: 1758 (73.8%) and late initiation: 623 (26.2%)). For infants born at more than 28 weeks of gestation, the adjusted generalised linear mixed model showed that the duration of invasive mechanical ventilation was 1.34 (95% CI −2.40 to –0.27) days shorter and the incidence of moderate-to-severe bronchopulmonary dysplasia (BPD) was lower (adjusted OR 0.63; 95% CI 0.41 to 0.96) in the early caffeine group compared with the late caffeine group.

Conclusion In very preterm infants who initially receive invasive mechanical ventilation, early administration of caffeine within 24 hours after birth can shorten the duration of invasive mechanical ventilation, reduce the incidence of moderate-to-severe BPD and improve respiratory outcomes. The very early initiation of caffeine treatment does not appear to be associated with any adverse outcomes.

Trial registration number ChiCTR1900025234.

  • Pulmonary Disease, Chronic Obstructive
  • Drug induced Lung Disease

Data availability statement

Data are available on reasonable request.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/bmjresp-2023-002285

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    WHAT IS ALREADY KNOWN ON THIS TOPIC

    • The guidelines recommend early caffeine administration for preterm infants requiring non-invasive mechanical ventilation since earlier treatment is associated with better outcomes. Can early caffeine use benefit very preterm infants with invasive mechanical ventilation?

    WHAT THIS STUDY ADDS

    • In very preterm infants who initially receive invasive mechanical ventilation, early administration of caffeine within 24 hours after birth can shorten the duration of invasive mechanical ventilation, reduce the incidence of moderate-to-severe bronchopulmonary dysplasia (BPD) and improve respiratory outcomes. The very early initiation of caffeine treatment does not appear to be associated with any adverse outcomes.

    HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

    • Early caffeine therapy reduced the duration of invasive mechanical ventilation, decreased the incidence of moderate-to-severe BPD and improved respiratory outcomes in very preterm infants who initially received invasive mechanical ventilation. In clinical practice, a rigorous observational cohort study can also provide a reliable source of evidence for clinical practice when randomised controlled trials cannot be performed.

    Introduction

    With the continuous improvement of neonatal care, the survival rate of very premature infants has significantly increased. However, due to the presence of underdeveloped lungs, bronchopulmonary dysplasia (BPD) remains a poor outcome in these very premature infants.1 2 Our previous study showed that the median duration of invasive mechanical ventilation was 26 (17–41) days in very preterm infants, and a longer duration of invasive mechanical ventilation was an independent risk factor for the development of moderate-to-severe BPD.3 The Caffeine for Apnoea of Prematurity (CAP) study confirmed that caffeine promoted successful extubation, reduced the incidence of BPD and improved neurodevelopmental outcomes in preterm infants.4 5

    With the publication of the CAP study results, clinical practice has changed in many centres, and the use of caffeine for prophylactic purposes has increased significantly (ie, administration is started very soon after birth or before a diagnosis of apnoea of prematurity is made).6 7 Subgroup analysis of the CAP trial showed that early use of caffeine within 72 hours after birth decreased the incidence of BPD.6 The European Consensus Guidelines recommend considering early administration of caffeine for infants at high risk of mechanical ventilation, such as premature infants receiving non-invasive mechanical ventilation.8 While international guidelines favour non-invasive respiratory support, the majority of preterm infants still inevitably require invasive mechanical ventilation after admission.9 Therefore, can the early use of caffeine improve respiratory outcomes in very preterm infants who initially receive invasive mechanical ventilation?

    We hypothesised that the early use of caffeine would provide similar benefits without evidence of short-term harm in very preterm infants who initially received invasive mechanical ventilation. The aim of this study, which was based on a prospective observational cohort study, was to determine whether early caffeine administration (within 24 hours after birth) contributes to early withdrawal and improved respiratory outcomes in very preterm infants who initially received initial invasive mechanical ventilation.

    Methods

    Study design and population

    This was a multicentre observation cohort study based on a database that was prospectively collected and maintained. The study included all preterm neonates who were born at less than 32 weeks of gestation and admitted to 47 participating NICUs in the Sino-Northern Neonatal Network (SNN) (http://www.snn-med.com/) from 1 January 2018 to 31 December 2022. Neonates who were born outside a tertiary-level NICU, who initially received non-invasive positive pressure ventilation, who had congenital anomalies, who did not receive caffeine therapy, who were missing data and who died before 24 hours after birth were excluded from the study.

    Data sources

    The data were collected as part of the SNN routine data collection.10 Prospectively, maternal pregnancy and delivery data were collected soon after birth, and infant data were collected until death and hospital discharge/transfer. Patients were divided into the following two groups according to the time of caffeine initiation: early initiation (neonates who received caffeine within the first 24 hours after birth) and late initiation (neonates who received caffeine starting ≥24 hours after birth). The usual practice in each centre is to administer a loading dose of 20 mg/kg of caffeine base, with a daily maintenance dose of 5–10 mg/kg initiated 24 hours after the loading dose.

    Outcomes

    The primary outcomes of this study were the duration of invasive mechanical ventilation and the incidence of moderate-to-severe BPD. The secondary outcomes were the duration of non-invasive respiratory support, the duration of oxygen supplementation, pulmonary haemorrhage, failure to wean, necrotising enterocolitis (NEC) and death before discharge.

    Definitions

    Estimates of gestational age were made, in descending order of preference, according to ultrasonography, the last menstrual period or the New Ballard score.11 The outcomes included early-onset sepsis (≤72 hours) (defined by cultures positive for bacteria or fungi and antibiotic therapy duration ≥5 days or the intention to treat but death <5 days),12 NEC (stages 2–3),13 severe intraventricular haemorrhage13 and moderate-to-severe BPD (the definition of moderate to severe BPD was based on previously published criteria by Jobe and Bancalari).14 The diagnosis of PDA was made clinically (a wide pulse pressure, prominent precordial pulsations, bounding pulses and a continuous systolic murmur at the second left parasternal area and/or signs of heart failure), with or without echocardiography.

    The duration of invasive mechanical ventilation was defined as the total number of days the infant required mechanical ventilation support. The duration of non-invasive respiratory support was defined as the total number of days during which the infant received nasal intermittent positive pressure ventilation, bilevel positive airway pressure, continuous positive airway pressure or high-flow nasal cannula therapy. The duration of oxygen supplementation was defined as the total number of days the infant received supplemental oxygen. Reintubation within 72 hours was defined as extubation failure.15

    Statistical analysis

    All the data were analysed by using SPSS V.26.0 software. Continuous variables are presented as medians (IQRs) while categorical variables are expressed as frequencies (percentages). The Mann-Whitney U test or χ2 test was used to compare the differences between the two groups according to the distribution of the data. To control for these potential confounding factors, participants in the two groups were matched 1:1 using propensity score matching based on statistically significant baseline characteristics (gestational age, birth weight and surfactant use). Any baseline characteristics that did not exhibit appropriate balance between the two groups were subsequently included in generalised linear mixed models. Generalised linear mixed models with a random effect model for the centre were used to assess the impact of different caffeine initiation times on neonatal outcomes. In this study, a p<0.05 was considered to indicate statistical significance.

    Results

    Baseline characteristics

    A total of 9880 infants born at <32 weeks gestation were admitted to participating NICUs during the study. Based on the inclusion and exclusion criteria, 2381 very preterm infants with initial invasive mechanical ventilation were ultimately included in this study; 1758 (73.8%) were included in the early initiation group and 623 (26.2%) were included in the late initiation group (figure 1).

    Figure 1
    Figure 1

    Flow diagram of the study participants.

    The baseline characteristics of the cohort are described in table 1. After propensity score matching, the majority of covariates were balanced between the two groups in both subcohorts. Compared with the late caffeine initiation group, the early initiation group (infants born at <28 weeks gestation) had a greater percentage of males and a somewhat lower Apgar score at 5 min (table 1). For infants born at 28+0–31+6 weeks gestation in the early initiation group, there were statistically significant differences in male sex and hsPDA (table 1).

    View this table:
    Table 1

    Demographic and clinical data by gestational age range

    Primary outcomes

    Univariate analysis of infants born at 28+0–31+6 weeks of gestation revealed that the duration of invasive mechanical ventilation (early initiation: median 4 days (IQR 2.5–7.9) vs late initiation: 6 (3.7–10.8) days, p<0.05) was shorter, and the risk of moderate-to-severe BPD (10.7% vs 16.2%; p=0.013) was lower in the infants for whom caffeine was given early than in those for whom it was given late (table 2). The adjusted generalised linear mixed model showed that the duration of invasive mechanical ventilation was 1.34 (95% CI −2.40 to –0.27; p=0.014) days shorter and the incidence of moderate-to-severe BPD was lower (adjusted OR, AOR 0.63; 95% CI 0.41 to 0.96) in the early caffeine group compared with the late caffeine group (table 2). For infants born at <28 weeks, univariate analysis revealed that the early caffeine group had a shorter duration of invasive mechanical ventilation (early initiation: median 8 days (IQR 4.2–21.3) vs late initiation: 14 (6.7–25.8) days; p=0.108) and a lower incidence of moderate-to-severe BPD (32.1% vs 34.9%; p=0.662) than the late caffeine group did, although the differences were not statistically significant (table 2).

    View this table:
    Table 2

    Comparison of outcomes between very preterm infants administered caffeine either within early group or late group

    Secondary outcomes

    For infants born at 28+0–31+6 weeks gestation, the adjusted generalised linear mixed model showed that the duration of oxygen supplementation was 5.38 lower (95% CI −8.10 to –2.66; p<0.001) in the early caffeine group compared with the late caffeine group (table 2). For infants born at <28 weeks, the adjusted generalised linear mixed model showed that the early caffeine group had a lower incidence of pulmonary haemorrhage (AOR 0.39; 95% CI 0.17 to 0.92) than the late caffeine group (table 2). Within both gestational age ranges, there were no statistically significant differences in the duration of non-invasive respiratory support, failure to wean or death before discharge between the two groups (p>0.05).

    Discussion

    Early caffeine administration is recommended for infants at high risk of needing mechanical ventilation, such as premature infants receiving non-invasive mechanical ventilation. For infants who initially receive invasive mechanical ventilation, whether caffeine should be applied early is still controversial. This was a large, multicentre, population-based cohort study conducted to investigate the association between early caffeine administration and respiratory outcomes among very preterm infants who initially received invasive mechanical ventilation in China. Despite the lack of evidence from randomised clinical trials evaluating the very early use of caffeine in preterm neonates, most very preterm neonates in Chinese neonatal intensive care units (NICUs) included in this study received caffeine within the first 24 hours after birth. In our study, the rate of early caffeine administration was 73.8% among very preterm infants. Borszewska-Kornacka et al16 reported that the proportion of very preterm infants treated early with caffeine citrate (initial dose on the first day of life) was 80.1%. In this study, we found no serious adverse effects associated with early (prophylactic) caffeine initiation in preterm infants (born at <32 weeks gestation) compared with those who received caffeine later.

    Multivariate analysis revealed that among infants born at 28+0–31+6 weeks gestation, early administration of caffeine was associated with a shorter duration of invasive mechanical ventilation. A randomised double-blind clinical trial showed that early caffeine initiation reduces reintubation.17 Infants who received caffeine early appeared to be ready for extubation earlier, and therefore, had a reduced duration of mechanical ventilation. A retrospective cohort study showed that the median duration of mechanical ventilation was reduced by 3 days in the early caffeine treatment group.4 Like in our study, Lodha et al18 reported that early caffeine application reduced the median duration of mechanical ventilation by 2 days. Early application of caffeine could improve the contraction and function of the diaphragm in very preterm infants, stimulate regular breathing and increase the sensitivity of the infant to carbon dioxide.19 20 Henderson-Smart and Davis21 reported that caffeine increases the chances of successful extubation of preterm infants within 1 week of birth. The results of our real-world study suggested that early caffeine administration within 24 hours after birth maximises the potential benefits among very preterm infants who initially receive invasive mechanical ventilation.

    Our study also revealed a significant reduction in the incidence of BPD in infants with a gestational age of 28+0–31+6 weeks in the early caffeine group compared with the late caffeine group. Previous studies have shown that prolonged mechanical ventilation is an independent risk factor for BPD, and early caffeine initiation can reduce the duration of mechanical ventilation.9 22 A retrospective cohort study conducted by the CNN showed that early caffeine administration reduced the incidence of BPD in very preterm infants.18 Another retrospective cohort study also showed that early caffeine administration was associated with a reduced incidence of BPD.23 These findings suggested that early administration of caffeine within 24 hours after birth has a greater benefit in improving the incidence of BPD than other early administration times. The decrease in the incidence of BPD in the early caffeine treatment group may be related to the mechanism of caffeine, in addition to the shorter duration of mechanical ventilation and oxygenation supplementation in the early caffeine treatment group. Early application of caffeine could reduce the expression levels of chemokines and leucocytes in oxidised lung tissue, weaken the apoptosis mediated by inflammatory factors and reduce the release of inflammatory mediators to improve lung function, thereby preventing the development of BPD in preterm infants.24 This study provides real evidence for the early use of caffeine in premature infants who initially receive initial mechanical ventilation.

    In extremely premature infants with a gestational age of less than 28 weeks, early caffeine administration also reduced the duration of invasive mechanical ventilation and the incidence of moderate-to-severe BPD. Although the difference was not statistically significant, there was still a trend towards improved respiratory outcomes. Respiratory maturity is lower in very preterm infants at a younger gestational age, and there may be many other factors that influence respiratory outcomes, such as genetic susceptibility,25 sepsis,26 patent ductus arteriosus,27 antibiotic application,28 admission hypothermia29 and lower socioeconomic status.30 Early caffeine administration did not dominate these factors, suggesting that early caffeine application alone did not result in significant improvement in respiratory outcomes in very preterm infants who were small for gestational age. In addition, the much smaller sample size and lower gestational age potentially impeded the ability to detect a significant difference.

    This study has several limitations. First, these findings should be interpreted with caution because of the observational nature of our study. Second, due to time constraints, this study focused only on the short-term effects of caffeine and did not explore the long-term effects. Third, for infants with gestational ages less than 28 weeks, it is necessary to increase the sample size for better evidence. Future studies are planned to investigate the effects of early caffeine administration on long-term outcomes in preterm infants.

    In conclusion, early caffeine therapy reduced the duration of invasive mechanical ventilation, decreased the incidence of moderate-to-severe BPD and improved respiratory outcomes in very preterm infants who initially received invasive mechanical ventilation. In clinical practice, a rigorous observational cohort study can also provide a reliable source of evidence for clinical practice when randomised controlled trials cannot be performed.

    Data availability statement

    Data are available on reasonable request.

    Ethics statements

    Patient consent for publication

    Ethics approval

    This study involves human participants and the Institutional Review Board of Shandong Provincial Hospital Affiliated with Shandong University approved the project (ethical approval number: LCYJ: No. 2019-132). Participants gave informed consent to participate in the study before taking part.

    References

    1. ↵
      1. Mowitz ME,
      2. Gao W,
      3. Sipsma H, et al
      . Long-term burden of respiratory complications associated with extreme prematurity: An analysis of US Medicaid claims. Pediatr Neonatol 2022;63:503–11. doi:10.1016/j.pedneo.2022.05.007
      OpenUrl
    2. ↵
      1. Siffel C,
      2. Hirst AK,
      3. Sarda SP, et al
      . The clinical burden of extremely preterm birth in a large medical records database in the United States: complications, medication use, and healthcare resource utilization. J Matern Fetal Neonatal Med 2022;35:10271–8. doi:10.1080/14767058.2022.2122035
      OpenUrl
    3. ↵
      1. Dou C,
      2. Yu Y-H,
      3. Zhuo Q-C, et al
      . Longer duration of initial invasive mechanical ventilation is still a crucial risk factor for moderate-to-severe bronchopulmonary dysplasia in very preterm infants: a multicentrer prospective study. World J Pediatr 2023;19:577–85. doi:10.1007/s12519-022-00671-w
      OpenUrl
    4. ↵
      1. Schmidt B,
      2. Roberts RS,
      3. Davis P, et al
      . Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112–21. doi:10.1056/NEJMoa054065
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      1. Schmidt B,
      2. Roberts RS,
      3. Davis P, et al
      . Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357:1893–902. doi:10.1056/NEJMoa073679
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      1. Dobson NR,
      2. Patel RM,
      3. Smith PB, et al
      . Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. J Pediatr 2014;164:992–8. doi:10.1016/j.jpeds.2013.12.025
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      1. Dekker J,
      2. Hooper SB,
      3. van Vonderen JJ, et al
      . Caffeine to improve breathing effort of preterm infants at birth: a randomized controlled trial. Pediatr Res 2017;82:290–6. doi:10.1038/pr.2017.45
      OpenUrlPubMed
    8. ↵
      1. Davis PG,
      2. Schmidt B,
      3. Roberts RS, et al
      . Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr 2010;156:382–7. doi:10.1016/j.jpeds.2009.09.069
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      1. Sweet DG,
      2. Carnielli VP,
      3. Greisen G, et al
      . European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology 2023;120:3–23. doi:10.1159/000528914
      OpenUrlCrossRefPubMed
    10. ↵
      1. Yu YH,
      2. Wang L,
      3. Zhang M, et al
      . Shandong multi-center clinical research group of quality improvement of premature infants admitted to NICU with hypothermia. Multicenter study on reducing the incidence of hypothermia on admission in very low birth weight infants using evidence-based quality improvement methods. Chin J Evid based Pediatr 2019;14:139–42. doi:10.3969/j.issn.1673-5501.2019.02.012
      OpenUrl
    11. ↵
      1. Ballard JL,
      2. Khoury JC,
      3. Wedig K, et al
      . New Ballard Score, expanded to include extremely premature infants. J Pediatr 1991;119:417–23. doi:10.1016/s0022-3476(05)82056-6
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      1. Stoll BJ,
      2. Hansen NI,
      3. Sánchez PJ, et al
      . Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011;127:817–26. doi:10.1542/peds.2010-2217
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      1. Shao X,
      2. Ye H,
      3. Qiu X
      . Practice of neonatology. 5th edn. People’s Medical Publishing House, 2019:p396, p408, p479; p702.
    14. ↵
      1. Jobe AH,
      2. Bancalari E
      . Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723–9. doi:10.1164/ajrccm.163.7.2011060
      OpenUrlCrossRefPubMed
    15. ↵
      1. Ohnstad MO,
      2. Stensvold HJ,
      3. Tvedt CR, et al
      . Duration of Mechanical Ventilation and Extubation Success among Extremely Premature Infants. Neonatology 2021;118:90–7. doi:10.1159/000513329
      OpenUrlPubMed
    16. ↵
      1. Borszewska-Kornacka MK,
      2. Hożejowski R,
      3. Rutkowska M, et al
      . Shifting the boundaries for early caffeine initiation in neonatal practice: Results of a prospective, multicenter study on very preterm infants with respiratory distress syndrome. PLoS One 2017;12:e0189152. doi:10.1371/journal.pone.0189152
    17. ↵
      1. Steer PA,
      2. Flenady VJ,
      3. Shearman A, et al
      . Periextubation caffeine in preterm neonates: a randomized dose response trial. J Paediatr Child Health 2003;39:511–5. doi:10.1046/j.1440-1754.2003.00207.x
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      1. Lodha A,
      2. Seshia M,
      3. McMillan DD, et al
      . Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr 2015;169:33–8. doi:10.1001/jamapediatrics.2014.2223
      OpenUrl
    19. ↵
      1. Parikka V,
      2. Beck J,
      3. Zhai Q, et al
      . The effect of caffeine citrate on neural breathing pattern in preterm infants. Early Hum Dev 2015;91:565–8. doi:10.1016/j.earlhumdev.2015.06.007
      OpenUrl
    20. ↵
      1. Aranda JV,
      2. Turmen T,
      3. Davis J, et al
      . Effect of caffeine on control of breathing in infantile apnea. J Pediatr 1983;103:975–8. doi:10.1016/s0022-3476(83)80735-5
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      1. Henderson-Smart DJ,
      2. Davis PG
      . Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010;CD000139:CD000139. doi:10.1002/14651858.CD000139.pub2
    22. ↵
      1. Jiangsu Province Neonatal Perinatal Cooperation Network
      . Risk factors for moderate/severe bronchopulmonary dysplasia in preterm infants with a gestational age of <32 weeks: a multicenter retrospective analysis. Zhong Dang Dai Er Ke Za Zhi 2022;24:1104–10. doi:10.7499/j.issn.1008-8830.2204145
      OpenUrl
    23. ↵
      1. Taha D,
      2. Kirkby S,
      3. Nawab U, et al
      . Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J Matern Fetal Neonatal Med 2014;27:1698–702. doi:10.3109/14767058.2014.885941
      OpenUrlCrossRefPubMed
    24. ↵
      1. Yuan Y,
      2. Yang Y,
      3. Lei X, et al
      . Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. Pediatr Pulmonol 2022;57:1392–400. doi:10.1002/ppul.25898
      OpenUrl
    25. ↵
      1. Kua KP,
      2. Lee SWH
      . Systematic review and meta-analysis of clinical outcomes of early caffeine therapy in preterm neonates. Br J Clin Pharmacol 2017;83:180–91. doi:10.1111/bcp.13089
      OpenUrlPubMed
    26. ↵
      1. Ebrahimi ME,
      2. Romijn M,
      3. Vliegenthart RJS, et al
      . The association between clinical and biochemical characteristics of late-onset sepsis and bronchopulmonary dysplasia in preterm infants. Eur J Pediatr 2021;180:2147–54. doi:10.1007/s00431-021-03981-9
      OpenUrl
    27. ↵
      1. Hamrick SEG,
      2. Sallmon H,
      3. Rose AT, et al
      . Patent Ductus Arteriosus of the Preterm Infant. Pediatrics 2020;146:e20201209. doi:10.1542/peds.2020-1209
    28. ↵
      1. Pei X,
      2. Gao Y,
      3. Kou Y, et al
      . Association of necrotizing enterocolitis with antimicrobial exposure in preterm infants <32 weeks gestational age:A multicenter prospective case-control study. Front Pharmacol 2022;13:976487. doi:10.3389/fphar.2022.976487
    29. ↵
      1. Yu Y-H,
      2. Wang L,
      3. Huang L, et al
      . Association between admission hypothermia and outcomes in very low birth weight infants in China: a multicentre prospective study. BMC Pediatr 2020;20:321. doi:10.1186/s12887-020-02221-7
    30. ↵
      1. Deschamps J,
      2. Boucekine M,
      3. Fayol L, et al
      . Neighborhood Disadvantage and Early Respiratory Outcomes in Very Preterm Infants with Bronchopulmonary Dysplasia. J Pediatr 2021;237:177–82. doi:10.1016/j.jpeds.2021.06.061
      OpenUrl

    Footnotes

    • LZ, MZ, SL, XS, XS, GY, CL and ML are joint first authors.

    • Contributors The guarantor of the manuscript is YY. YY, YZhao/YY and LW/YY conceptualised and designed the study and reviewed and revised the manuscript. YZhu/YY, LZ/YY, MZ/YY, SL/YY, XuemeiS/YY, XiaolinS/YY, GY/YY, CL/YY and ML/YY coordinated and supervised data collection, drafted the initial manuscript and reviewed and revised the manuscript. CS/YY and HH/YY carried out the analyses, interpreted the results, drafted the initial manuscript, and reviewed and revised the manuscript. YJ/YY and BJ/YY contributed to data collection and reviewed and revised the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.

    • Funding This study was supported by the Shandong Medical Association Clinical Research Fund-Qilu Special Project (YXH2022DZX0200X).

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; externally peer reviewed.